The performance of metagenomic next-generation sequencing in diagnosing pulmonary infectious diseases using authentic clinical specimens: The Illumina platform versus the Beijing Genomics Institute platform

Introduction: Metagenomic next-generation sequencing (mNGS) has been increasingly used to detect infectious organisms and is rapidly moving from research to clinical laboratories. Presently, mNGS platforms mainly include those from Illumina and the Beijing Genomics Institute (BGI). Previous studies...

Full description

Bibliographic Details
Main Authors: Shuangyu Han, Zhan Zhao, Lei Yang, Jie Huang, Yubao Wang, Jing Feng
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1164633/full
_version_ 1797845586825707520
author Shuangyu Han
Zhan Zhao
Lei Yang
Jie Huang
Yubao Wang
Jing Feng
author_facet Shuangyu Han
Zhan Zhao
Lei Yang
Jie Huang
Yubao Wang
Jing Feng
author_sort Shuangyu Han
collection DOAJ
description Introduction: Metagenomic next-generation sequencing (mNGS) has been increasingly used to detect infectious organisms and is rapidly moving from research to clinical laboratories. Presently, mNGS platforms mainly include those from Illumina and the Beijing Genomics Institute (BGI). Previous studies have reported that various sequencing platforms have similar sensitivity in detecting the reference panel that mimics clinical specimens. However, whether the Illumina and BGI platforms provide the same diagnostic performance using authentic clinical samples remains unclear.Methods: In this prospective study, we compared the performance of the Illumina and BGI platforms in detecting pulmonary pathogens. Forty-six patients with suspected pulmonary infection were enrolled in the final analysis. All patients received bronchoscopy, and the specimens collected were sent for mNGS on the two different sequencing platforms.Results: The diagnostic sensitivity of the Illumina and BGI platforms was notably higher than that of conventional examination (76.9% vs. 38.5%, p < 0.001; 82.1% vs. 38.5%, p < 0.001; respectively). The sensitivity and specificity for pulmonary infection diagnosis were not significantly different between the Illumina and BGI platforms. Furthermore, the pathogenic detection rate of the two platforms were not significantly different.Conclusion: The Illumina and BGI platforms exhibited similar diagnostic performance for pulmonary infectious diseases using clinical specimens, and both are superior to conventional examinations.
first_indexed 2024-04-09T17:41:24Z
format Article
id doaj.art-1f7ea5a4da6a411fb3e90e53baf0d867
institution Directory Open Access Journal
issn 1663-9812
language English
last_indexed 2024-04-09T17:41:24Z
publishDate 2023-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj.art-1f7ea5a4da6a411fb3e90e53baf0d8672023-04-17T05:02:02ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-04-011410.3389/fphar.2023.11646331164633The performance of metagenomic next-generation sequencing in diagnosing pulmonary infectious diseases using authentic clinical specimens: The Illumina platform versus the Beijing Genomics Institute platformShuangyu HanZhan ZhaoLei YangJie HuangYubao WangJing FengIntroduction: Metagenomic next-generation sequencing (mNGS) has been increasingly used to detect infectious organisms and is rapidly moving from research to clinical laboratories. Presently, mNGS platforms mainly include those from Illumina and the Beijing Genomics Institute (BGI). Previous studies have reported that various sequencing platforms have similar sensitivity in detecting the reference panel that mimics clinical specimens. However, whether the Illumina and BGI platforms provide the same diagnostic performance using authentic clinical samples remains unclear.Methods: In this prospective study, we compared the performance of the Illumina and BGI platforms in detecting pulmonary pathogens. Forty-six patients with suspected pulmonary infection were enrolled in the final analysis. All patients received bronchoscopy, and the specimens collected were sent for mNGS on the two different sequencing platforms.Results: The diagnostic sensitivity of the Illumina and BGI platforms was notably higher than that of conventional examination (76.9% vs. 38.5%, p < 0.001; 82.1% vs. 38.5%, p < 0.001; respectively). The sensitivity and specificity for pulmonary infection diagnosis were not significantly different between the Illumina and BGI platforms. Furthermore, the pathogenic detection rate of the two platforms were not significantly different.Conclusion: The Illumina and BGI platforms exhibited similar diagnostic performance for pulmonary infectious diseases using clinical specimens, and both are superior to conventional examinations.https://www.frontiersin.org/articles/10.3389/fphar.2023.1164633/fullmetagenomic next-generation sequencingIlluminaBGIconventional examinationpulmonary infection
spellingShingle Shuangyu Han
Zhan Zhao
Lei Yang
Jie Huang
Yubao Wang
Jing Feng
The performance of metagenomic next-generation sequencing in diagnosing pulmonary infectious diseases using authentic clinical specimens: The Illumina platform versus the Beijing Genomics Institute platform
Frontiers in Pharmacology
metagenomic next-generation sequencing
Illumina
BGI
conventional examination
pulmonary infection
title The performance of metagenomic next-generation sequencing in diagnosing pulmonary infectious diseases using authentic clinical specimens: The Illumina platform versus the Beijing Genomics Institute platform
title_full The performance of metagenomic next-generation sequencing in diagnosing pulmonary infectious diseases using authentic clinical specimens: The Illumina platform versus the Beijing Genomics Institute platform
title_fullStr The performance of metagenomic next-generation sequencing in diagnosing pulmonary infectious diseases using authentic clinical specimens: The Illumina platform versus the Beijing Genomics Institute platform
title_full_unstemmed The performance of metagenomic next-generation sequencing in diagnosing pulmonary infectious diseases using authentic clinical specimens: The Illumina platform versus the Beijing Genomics Institute platform
title_short The performance of metagenomic next-generation sequencing in diagnosing pulmonary infectious diseases using authentic clinical specimens: The Illumina platform versus the Beijing Genomics Institute platform
title_sort performance of metagenomic next generation sequencing in diagnosing pulmonary infectious diseases using authentic clinical specimens the illumina platform versus the beijing genomics institute platform
topic metagenomic next-generation sequencing
Illumina
BGI
conventional examination
pulmonary infection
url https://www.frontiersin.org/articles/10.3389/fphar.2023.1164633/full
work_keys_str_mv AT shuangyuhan theperformanceofmetagenomicnextgenerationsequencingindiagnosingpulmonaryinfectiousdiseasesusingauthenticclinicalspecimenstheilluminaplatformversusthebeijinggenomicsinstituteplatform
AT zhanzhao theperformanceofmetagenomicnextgenerationsequencingindiagnosingpulmonaryinfectiousdiseasesusingauthenticclinicalspecimenstheilluminaplatformversusthebeijinggenomicsinstituteplatform
AT leiyang theperformanceofmetagenomicnextgenerationsequencingindiagnosingpulmonaryinfectiousdiseasesusingauthenticclinicalspecimenstheilluminaplatformversusthebeijinggenomicsinstituteplatform
AT jiehuang theperformanceofmetagenomicnextgenerationsequencingindiagnosingpulmonaryinfectiousdiseasesusingauthenticclinicalspecimenstheilluminaplatformversusthebeijinggenomicsinstituteplatform
AT yubaowang theperformanceofmetagenomicnextgenerationsequencingindiagnosingpulmonaryinfectiousdiseasesusingauthenticclinicalspecimenstheilluminaplatformversusthebeijinggenomicsinstituteplatform
AT jingfeng theperformanceofmetagenomicnextgenerationsequencingindiagnosingpulmonaryinfectiousdiseasesusingauthenticclinicalspecimenstheilluminaplatformversusthebeijinggenomicsinstituteplatform
AT shuangyuhan performanceofmetagenomicnextgenerationsequencingindiagnosingpulmonaryinfectiousdiseasesusingauthenticclinicalspecimenstheilluminaplatformversusthebeijinggenomicsinstituteplatform
AT zhanzhao performanceofmetagenomicnextgenerationsequencingindiagnosingpulmonaryinfectiousdiseasesusingauthenticclinicalspecimenstheilluminaplatformversusthebeijinggenomicsinstituteplatform
AT leiyang performanceofmetagenomicnextgenerationsequencingindiagnosingpulmonaryinfectiousdiseasesusingauthenticclinicalspecimenstheilluminaplatformversusthebeijinggenomicsinstituteplatform
AT jiehuang performanceofmetagenomicnextgenerationsequencingindiagnosingpulmonaryinfectiousdiseasesusingauthenticclinicalspecimenstheilluminaplatformversusthebeijinggenomicsinstituteplatform
AT yubaowang performanceofmetagenomicnextgenerationsequencingindiagnosingpulmonaryinfectiousdiseasesusingauthenticclinicalspecimenstheilluminaplatformversusthebeijinggenomicsinstituteplatform
AT jingfeng performanceofmetagenomicnextgenerationsequencingindiagnosingpulmonaryinfectiousdiseasesusingauthenticclinicalspecimenstheilluminaplatformversusthebeijinggenomicsinstituteplatform